Overview

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO.

Participation in the study will last about 18 months.

Eligibility

Inclusion Criteria:

• Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
• Have type 2 diabetes
• Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
• Have a history of at least one unsuccessful dietary effort to lose body weight

Exclusion Criteria:

• Have type 1 diabetes
• Have an unstable body weight within 90 days prior to screening
• Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
• Have acute or chronic hepatitis or pancreatitis
• Are taking other medications or alternative remedies to manage weight loss